Fms-like Tyrosine Kinase 3 | Protein Tyrosine Kinase/RTK| CSNpharm

FLT3

FLT3

Items: 1–10 of

Show:

50

20

50

100

Cat. No.	Product Name	CAS No.	Information
CSN15695	UNC2025	1429881-91-3	UNC2025 is an inhibitor of Mer and Flt3 with IC50 of 08 nM and 074 nM respectively
CSN19156	UNC2025 HCl	2070015-17-5	UNC2025 HCl is a potent and orally bioavailable MerFlt3 dual inhibitor with IC50 of 08074 nM for MerFlt3
CSN13941	TCS 359	301305-73-7	TCS 359 a 2-acylaminothiophene-3-carboxamide is a potent inhibitor of FLT3 with IC50 of 42 nM
CSN12033	Tandutinib	387867-13-2	Tandutinib is an antagonist of FLT3 with IC50 of 0.22 M and can also inhibit PDGFR and c-Kit thereby inhibiting cellular proliferation and inducing apoptosis.
CSN24785	TAK-659	1312691-33-0	TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC50 of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL)[1][2][3][4].
CSN20533	SU-5614	1055412-47-9	SU-5614 is an inhibitor of FLT3 In BaF3 and AML cell lines expressing a constitutively activated FLT3 SU-5614 exhibits significant cell growth inhibition and cell cycle arrest
CSN13100	Quizartinib	950769-58-1	Quizartinib is a second-generation FLT3 inhibitor for Flt3 ITDWT with IC50 of 11 nM42 nM being 10-fold selective for Flt3 than KIT PDGFR PDGFR RET and CSF-1R
CSN17304	KW-2449	1000669-72-6	KW-2449 is a multiple-targeted inhibitor mostly for Flt3 with IC50 of 66 nM modestly potent to FGFR1 Bcr-Abl and Aurora A and showing little effect on PDGFR IGF-1R EGFR
CSN13926	Gilteritinib	1254053-43-4	Gilteritinib is a potent FLT3AXL inhibitor with IC50 of 029 nM 1 nM respectively and shows potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations
CSN21227	Gilteritinib Hemifumarate	1254053-84-3	Gilteritinib hemifumarate is an inhibitor of FLT3 and AXL with IC50 of 0.29 nM and 0.73 nM, respectively.
CSN13783	G-749	1457983-28-6	G-749 is a FLT3 inhibitor that showed potent and sustained inhibition of the FLT3 wild type and mutants with IC50s of 04063575 nM for Wt Flt3D835YMV4-11Molm-14 respectively
CSN16867	FLT3-IN-2	923562-23-6	FLT3-IN-2 is a FLT3 inhibitor with IC50 of 1 M
CSN21240	FLT3-IN-1 Succinate	1702864-11-6	FLT3-IN-1 Succinate is a potent FLT3 inhibitor extracted from patent WO2015056683A1 compound example A
CSN21235	FLT3-IN-1	1472797-69-5	FLT3-IN-1 is a potent FLT3 inhibitor extracted from patent WO2015056683A1 compound example A
CSN16265	SKLB4771	1370256-78-2	FLT3-IN-1 is a potent and selective Flt3 inhibitor with IC50 of 10 nM and against FLT3-ITD-expressing MV4-11 cells with IC50 of 6 nM
CSN27527	Fedratinib hydrochloride hydrate	1374744-69-0	Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research.
CSN20591	Famitinib	1044040-56-3	Famitinib a structural analogue of sunitinib is a multi-targeted receptor tyrosine kinase inhibitor which is potential for treatment of renal cell carcinoma gastrointestinal stromal tumours pancreatic cancer and nasopharyngeal carcinoma
CSN16610	ENMD-2076 Tartrate	1453868-32-0	ENMD-2076 tartrate has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 186 nM 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2KDR and VEGFR3 FGFR1 and FGFR2 and PDGFR
CSN18598	ENMD-2076	934353-76-1	ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 186 nM 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2KDR and VEGFR3 FGFR1 and FGFR2 and PDGFR
CSN24802	DBPR114	2443767-35-7	DBPR114 is a potent multi-kinase inhibitor with potent activities against more than 57 oncogenic kinases, including Aurora-A, FLT3, CSF1R, MET, etc. DBPR114 exhibited favorable PK profiles: a long half-life (t1/2 = 23.5 h), moderate clearance and high volume of distribution. Also DBPR114 can effectively inhibit the growth of human acute myeloid leukemia MOLM-13 and MV4-11, MIA PaCa-2, Hep3B, MKN45, Colo205, and NTUB1 solid tumor xenografts in vivo without causing significant body weight loss.
CSN16269	CTX-0294885	1439934-41-4	CTX-0294885 is a bisanilino pyrimidine and exhibits inhibitory activity against a broad range of kinases in vitro, further developed into a Sepharose-supported kinase capture reagent.
CSN18820	Crotonoside	1818-71-9	Crotonoside is a naturally occurring active isomer of guanosine found in the seeds of Croton tiglium, which could reduce the blood pressure in rabbits and cats.
CSN22754	CHMFL-FLT3-122	1839150-56-9	CHMFL-FLT3-122 is a potent and selective FLT3 inhibitor with IC50 of 40 nM.
CSN27200	CCT241736	1402709-93-6	CCT241736 is a dual FLT3/Aurora kinase A/B inhibitor with IC50 values of 0.035μM, 0.015μM and 0.1μM, respectively.
CSN16257	BPR1J-097	1327167-19-0	BPR1J-097 is a small molecule FLT-3 inhibitor IC50117 nM with promising in vivo anti-tumour activities inhibiting FLT-3 D835Y with an IC50 of 3 nM
CSN22922	BLU-667	2097132-94-8	Blu667 is a highly potent and selective RET inhibitor with IC50 value of 0.4nM.
CSN19120	BBT594	882405-89-2	BBT594 is a potentreceptor tyrosine kinase RET inhibitor, used for cancer treatment.
CSN25237	ATH686	853299-52-2	ATH686 is the second-generation FLT3 inhibitor.
CSN22654	5'-Fluoroindirubinoxime	861214-33-7	5'-Fluoroindirubinoxime is an inhibitor of FMS-like receptor tyrosine kinase-3 (FLT3) with IC50 of 15 nM.

<< PREV 1 2 NEXT >>

FLT3 Items: 1–10 of Show: 50 20 50 100

50

FLT3

Items: 1–10 of

Show:

50

20

50

100